| Product name |  SC5b-9 Plus MicroVue™ Quidel® | 
  
   |  | 
     Quantification of the SC5b-9 complex | 
  
   | Cat-No. | A029 | 
  
   | Range | 10 - 170 ng/ml | 
  
   | Sensitivity | LOD: 3.7 ng/ml; LLOQ: 8.8 ng/ml | 
  
   | Incubation time | 2 hours | 
  
   | Sample volume | 10 µl (dilute 1:40 for serum); 50 µl (dilute 1:10 for plasma) | 
  
   | Sample type | 
     Serum, EDTA plasma, spinal fluid or other biological fluids | 
  
   | Sample preparation | 
     The proper collection and storage of specimens is essential since SC5b-9 may be generated in improperly handled specimens. Serum or EDTA plasma specimens should be collected aseptically using standard techniques.They should be tested immediately or stored at 4 ºC or on ice until assayed. This should not exceed four hours. For longer-term storage freeze at -70 ºC. Plasma concentrations better reflect in vivo concentrations in comparison to serum concentrations.
 | 
  
   | Reference values | 
     Serum              334 - 1672 ng/mlEDTA Plasma     127 - 303 ng/ml
 | 
  
   | Species | 
     Human, cynomolgus macaque, baboon, rhesus macaque | 
  
   | Specificity | 
     Monoclonal mouse-antibody, specifically binds SC5b-9. | 
  
   | Tests | 96 Tests | 
  
   | Method | ELISA | 
  
   | Product informations | - Literature: Complement Diagnostics (pdf-File 1,850 kb) - Kit Instructions (pdf-File 185 kb)
 - Cross-reaction all species (pdf-File 71 kb)
 - Datasheet (pdf-File 511 kb)
 - Information (pdf-File 680 kb)
 - Information: Monitoring Complement Activation SC5b-9, C5a &CH50 (pdf-File 100 kb)
 | 
  
   | Intended use | 
     The SC5b-9 enzyme immunoassay measures the amount of SC5b-9 present in human plasma, serum and other biological or experimental samples.The Terminal Complement Complex (TCC, SC5b-9) is generated by the assembly of C5 through C9 as a consequence of activation of the complement system by either the classical, lectin or alternative pathway. The membrane attack complex (MAC), a form of TCC, is a stable complex that mediates the irreversible target cell membrane damage associated with complement activation.
 | 
  
   | Keywords product | 
     SC5b-9 Plus, ELISA, SC5b-9 Complex, Terminal complement pathway, Biocompatibility, Hemocompatibility, Complement pathway, Complement cascade, ASTM F1984-99, ASTM F2065-00 |